Many of the delays that surface during a clinical trial trace back to decisions made months earlier, before a single patient is enrolled. When questions about study design or regulatory strategy remain unresolved at that stage, they tend to resurface later as amendments or execution setbacks.

IQVIA helps sponsors strengthen these early decisions through its predictive approach to clinical development, working to reduce uncertainty before it becomes a downstream delay.

Explore IQVIA R&D Consulting Solutions

Predictive Clinical Development helps sponsors potential delays earlier, so they can be addressed before they slow down a study. IQVIA doesn’t make decisions for sponsors. We give them the data and experience, to make decisions earlier. By bringing the right development expertise together upfront, IQVIA helps sponsors anticipate risk and build protocols that are both effective and executable.

Explore IQVIA Research and Development Solutions

Patient population assumptions shape the study from the start. Testing them before the protocol is finalized helps sponsors identify gaps while the study design can still be adjusted. 

IQVIA uses real-world data and evidence to understand how patients are treated and what happens in practice. These insights give sponsors a stronger foundation for designing feasible protocols that reflect the patients they intend to study. 

Optimizing protocol design early gives sponsors the opportunity to pressure-test key decisions before they become costly to change.

IQVIA combines datawith development expertise to identify potential issues and refine the protocol while there is still flexibility to do so. This can reduce unnecessary complexity the risk of amendments later in the study. 

Early planning helps sponsors understand what evidence they will need and how data will move through the study before execution begins.

IQVIA brings clinical trial data, and real-world evidence together to test assumptions and identify potential issues before they affect execution or create problems later.

Explore Clinical Data Management Solutions

The key consideration is whether critical decisions are still open to influence. If they are, earlier engagement gives sponsors more opportunity to test assumptions and address potential risks while changes are easier to make. 

This can be particularly valuable for programs where complexity or uncertainty could affect the study downstream.

Explore Early Phase Clinical Development Solutions